Aztreonam lysine: Interim Phase III data

Gilead reported data from 72 evaluable patients who received 75 mg of aztreonam 3 times daily in the ongoing, open-label Phase III AIR-CF3 trial. After 12 months, patients had a mean 5.2% improvement ...